BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11929778)

  • 1. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
    Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
    Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
    Zheng P; Wu Y; Guo Y; Lee C; Liu Y
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
    Wu Y; Guo Y; Huang A; Zheng P; Liu Y
    J Exp Med; 1997 Apr; 185(7):1327-35. PubMed ID: 9104819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
    Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
    J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
    LaBelle JL; Hanke CA; Blazar BR; Truitt RL
    Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
    Fallarino F; Fields PE; Gajewski TF
    J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen.
    Huang TH; Wu PY; Lee CN; Huang HI; Hsieh SL; Kung J; Tao MH
    Blood; 2000 Dec; 96(12):3663-70. PubMed ID: 11090045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.
    Denfeld RW; Dietrich A; Wuttig C; Tanczos E; Weiss JM; Vanscheidt W; Schöpf E; Simon JC
    Int J Cancer; 1995 Jul; 62(3):259-65. PubMed ID: 7543078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of CD4 T cell changes in murine AIDS is dependent on costimulation and involves a dysregulation of homeostasis.
    Yen MH; Lepak N; Swain SL
    J Immunol; 2002 Jul; 169(2):722-31. PubMed ID: 12097374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction properties of costimulatory molecules revisited.
    Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
    Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
    Lane P
    Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 15. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis.
    Shao H; Woon MD; Nakamura S; Sohn JH; Morton PA; Bora NS; Kaplan HJ
    Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2016-21. PubMed ID: 11481266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens.
    Bai XF; Bender J; Liu J; Zhang H; Wang Y; Li O; Du P; Zheng P; Liu Y
    J Immunol; 2001 Oct; 167(7):3936-43. PubMed ID: 11564812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of B7 costimulation in T-cell immunity.
    Harris NL; Ronchese F
    Immunol Cell Biol; 1999 Aug; 77(4):304-11. PubMed ID: 10457196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
    Mandelbrot DA; McAdam AJ; Sharpe AH
    J Exp Med; 1999 Jan; 189(2):435-40. PubMed ID: 9892625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of conserved amino acids in murine B7-1IgV domain critical for CTLA4/CD28:B7 interaction by site-directed mutagenesis: a novel structural model of the binding site.
    Guo Y; Wu Y; Kong X; Liu Y
    Mol Immunol; 1998 Mar; 35(4):215-25. PubMed ID: 9736337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.